Sarepta Therapeutics 경영진
경영진 기준 점검 1/4
Sarepta Therapeutics CEO는 Doug Ingram, Jun2017 에 임명되었습니다 의 임기는 8.92 년입니다. 총 연간 보상은 $7.84M, 14.9% 급여 및 85.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $8.43M 가치에 해당하는 회사 주식의 0.37% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 0.8 년과 10 년입니다.
핵심 정보
Doug Ingram
최고경영자
US$7.8m
총 보수
| CEO 급여 비율 | 14.94% |
| CEO 재임 기간 | 8.9yrs |
| CEO 지분 보유율 | 0.4% |
| 경영진 평균 재임 기간 | less than a year |
| 이사회 평균 재임 기간 | 10yrs |
최근 경영진 업데이트
We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right
May 29
Recent updates
SRPT: 2026 Guidance And siRNA Pipeline Readouts Will Shape Upside Potential
Sarepta Therapeutics' updated analyst price target has shifted modestly, reflecting a lower fair value estimate of $37.42 and a reduced future P/E assumption as analysts weigh mixed siRNA data, updated 2026 revenue guidance, and varying views on Elevidys and the PMO franchise. Analyst Commentary Recent Street research on Sarepta shows a wide range of views, but several bullish analysts are leaning into updated company guidance and new clinical datapoints when revisiting their models.
SRPT: Future Returns Will Depend On 2026 Reset And Mixed Pipeline Signals
Analysts have lifted the blended price target for Sarepta Therapeutics by about $1 to $2, reflecting recent target revisions that balance cautious views on Elevidys revenue guidance and siRNA data quality with more constructive perspectives on early DM1 results and updated 2026 sales and expense models. Analyst Commentary Recent research paints a mixed picture for Sarepta, with analysts updating models around Elevidys, siRNA programs, and early DM1 data.Sarepta Therapeutics: A $2B Business Priced Like It's Broken
Mar 24SRPT: Future Upside Will Hinge On 2026 Gene Therapy Launch Reset
Analysts made a modest upward adjustment to Sarepta Therapeutics' fair value estimate, reflecting updated models around Elevidys launch pacing, 2026 revenue guidance, and revised expectations for profitability and future P/E multiples following recent Q4 results and regulatory commentary. Analyst Commentary Street research on Sarepta around the Q4 update and 2026 guidance reflects a wide range of views on execution risk, Elevidys launch pacing, and the durability of the exon-skipping and gene therapy portfolio.SRPT: Future Upside Will Depend On 2026 Gene Therapy Execution
The analyst price target for Sarepta Therapeutics has moved slightly lower to align with revised 2026 revenue expectations and product launch assumptions, with recent Street targets stepping down in a range from about $45 to $8 as analysts recalibrate Elevidys and other franchise contributions. Analyst Commentary Street views on Sarepta are split, with several firms cutting price targets after management issued 2026 revenue guidance that appears lower than earlier assumptions, while others still see room for execution on the Elevidys and exon-skipping franchises to support value over time.SRPT: Future Risk Reward Will Hinge On Elevidys Execution And Patent Overhang
The analyst price target for Sarepta Therapeutics has been raised by about $0.80. Analysts point to slightly higher fair value estimates, a modestly firmer long term profit margin outlook and updated P/E assumptions, even as they factor in a slightly higher discount rate and restrained revenue expectations.SRPT: Upcoming 2026 Clinical And Regulatory Milestones Will Drive Future Upside
Analysts have edged their price targets on Sarepta Therapeutics higher, with a modest fair value increase of about $0.20 per share. Slightly stronger long run profit expectations more than offset softer modeled revenue growth and a small trim to the assumed future P/E multiple.SRPT: Gene Therapy Catalysts And Access Updates Will Drive Future Upside
Analysts nudged their price target on Sarepta Therapeutics slightly higher, lifting fair value by about US$0.33 to US$39.90 as they factor in updated expectations for Elevidys sales, profitability, and a modestly higher discount rate. Analyst Commentary Recent research on Sarepta highlights a split view on Elevidys, with some pointing to softer near term sales and others focusing on what they see as growing adoption and a broader pipeline story.SRPT: Elevidys Adoption And Pipeline Progress Will Drive Future Upside
Analysts have reset their fair value estimate for Sarepta Therapeutics from US$55.90 to US$39.56. This reflects updated assumptions for revenue growth, profit margins, and a higher future P/E multiple following recent research that highlights both improved confidence in Elevidys adoption and ongoing caution from some covering firms.SRPT: Future Risk Reward Will Hinge On Evolving Safety And Coverage Decisions
The analyst price target for Sarepta Therapeutics has been raised slightly, by about $0.20 per share. Analysts attribute this to stronger than expected Elevidys adoption, supportive payer coverage, and a more favorable risk and reward profile, despite unchanged long-term growth and margin assumptions.SRPT: Safety Reviews And Payer Decisions Will Shape Future Risk Reward Balance
Sarepta Therapeutics' fair value estimate has been raised modestly to approximately $20.43 from $19.91, as analysts factor in stronger than expected Elevidys adoption and a more favorable risk or reward profile, despite only incremental improvements in revenue growth and discount rate assumptions. Analyst Commentary Street research on Sarepta has turned more constructive at the margin, with multiple models recalibrated around stronger Elevidys uptake and a clearer path to reimbursement.There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise
Dec 04SRPT: Ongoing Regulatory Reviews And Safety Updates Will Shape Near-Term Prospects
The analyst price target for Sarepta Therapeutics has been modestly reduced from approximately $21.55 to $19.91. Analysts express mixed expectations based on recent shifts in profit margin projections and ongoing evaluations of Elevidys adoption and safety dynamics.SRPT: Upcoming Clinical Data Will Drive Renewed Momentum In Gene Therapy Efforts
Sarepta Therapeutics' analyst price target has been revised downward from approximately $22.88 to $21.55 per share. Analysts cite ongoing concerns over Elevidys uptake, modest improvements to revenue outlook, and persistent profit margin pressures.Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry
Oct 18Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust
Sarepta Therapeutics’ consensus price target has been lowered from $23.96 to $22.88, primarily due to ongoing Elevidys safety concerns, regulatory uncertainty, and negative sentiment over recent management decisions, outweighing the short-term relief from improved liquidity and regulatory clarity. Analyst Commentary Elevidys safety concerns, including recent patient deaths and new serious adverse event reports, have sustained regulatory uncertainty and contributed to ongoing negative sentiment and price target reductions by Bearish analysts.Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust
Sarepta Therapeutics’ price target remains under pressure due to persistent safety concerns and regulatory uncertainty surrounding Elevidys, limited market scope after clinical setbacks and halted non-ambulatory development, and skepticism about long-term cash generation, resulting in a maintained consensus analyst price target of $23.84. Analyst Commentary Continued safety concerns surrounding Elevidys, particularly following patient deaths and serious adverse events (notably acute liver failure in non-ambulatory patients and new adverse event reports), have caused repeated reductions in revenue forecasts and increased uncertainty about regulatory approval and commercial uptake.We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right
May 29The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot
May 08Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 20Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Mar 18Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Low P/S No Reason For Excitement
Mar 05Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
Mar 04These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well
Jan 22Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Jan 16Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 13Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Dec 31 2025 | US$8m | US$1m | -US$713m |
| Sep 30 2025 | n/a | n/a | -US$272m |
| Jun 30 2025 | n/a | n/a | -US$58m |
| Mar 31 2025 | n/a | n/a | -US$248m |
| Dec 31 2024 | US$2m | US$847k | US$235m |
| Sep 30 2024 | n/a | n/a | US$122m |
| Jun 30 2024 | n/a | n/a | US$47m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$2m | US$800k | -US$536m |
| Sep 30 2023 | n/a | n/a | -US$691m |
| Jun 30 2023 | n/a | n/a | -US$908m |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$125m | US$740k | -US$703m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$507m |
| Mar 31 2022 | n/a | n/a | -US$357m |
| Dec 31 2021 | US$2m | US$730k | -US$419m |
| Sep 30 2021 | n/a | n/a | -US$486m |
| Jun 30 2021 | n/a | n/a | -US$634m |
| Mar 31 2021 | n/a | n/a | -US$704m |
| Dec 31 2020 | US$1m | US$669k | -US$554m |
| Sep 30 2020 | n/a | n/a | -US$601m |
| Jun 30 2020 | n/a | n/a | -US$530m |
| Mar 31 2020 | n/a | n/a | -US$656m |
| Dec 31 2019 | US$1m | US$650k | -US$715m |
보상 대 시장: Doug의 총 보수(USD7.84M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.47M)보다 높습니다.
보상과 수익: Doug의 보상은 회사가 적자임에도 증가했습니다.
CEO
Doug Ingram (62 yo)
8.9yrs
재임 기간
US$7,840,666
보수
Mr. Douglas S. Ingram, J.D., Esq., also known as Doug, served as Independent Director of Arrowhead Pharmaceuticals, Inc. since February 06, 2025 until March 20, 2026. He has been Chief Executive Officer Sa...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 8.9yrs | US$7.84m | 0.37% $ 8.4m | |
| President & COO | less than a year | US$4.44m | 0.030% $ 674.7k | |
| Executive VP & CFO | less than a year | US$3.21m | 0.011% $ 248.9k | |
| Executive VP | 1.5yrs | US$4.23m | 데이터 없음 | |
| President of Research & Development and Technical Operations | less than a year | US$4.46m | 0.052% $ 1.2m | |
| Chief Scientific Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Director of Finance | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief People Officer | 4.6yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP and Chief of Global Policy & Advocacy Officer | 6.7yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Commercial Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Medical Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Controller & VP | 9.2yrs | US$911.89k | 데이터 없음 |
0.8yrs
평균 재임 기간
53yo
평균 나이
경험이 풍부한 관리: SRPT의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 0.8 년) — 신규 팀일 수 있습니다.
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 8.9yrs | US$7.84m | 0.37% $ 8.4m | |
| Independent Chairwoman | 17.2yrs | US$603.92k | 0.20% $ 4.5m | |
| Chairman of Corporate Strategy Board & Independent Non-Employee Director | 15.9yrs | US$562.47k | 0.024% $ 544.9k | |
| Independent Director | 10.9yrs | US$577.28k | 3.06% $ 69.5m | |
| Member of Strategic & Scientific Advisory Board | 10.8yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 1.7yrs | US$558.15k | 0.0032% $ 71.9k | |
| Member of Strategic & Scientific Advisory Board | 10.8yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Employee Director | 10.9yrs | US$554.47k | 0.030% $ 681.3k | |
| Member of Strategic & Scientific Advisory Board | 9.2yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 6.4yrs | 데이터 없음 | 데이터 없음 | |
| Member of Strategic & Scientific Advisory Board | 9.2yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 6.5yrs | 데이터 없음 | 데이터 없음 |
10.0yrs
평균 재임 기간
69yo
평균 나이
경험이 풍부한 이사회: SRPT의 이사회는 경험이 있음으로 간주됩니다(평균 재임 10 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/03 02:51 |
| 종가 | 2026/05/01 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Sarepta Therapeutics, Inc.는 49명의 분석가가 다루고 있습니다. 이 중 20명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |